| ¿µ¹® | reserve cell | ÇÑ±Û | ¿¹ºñ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼ ÀÌ¹Ì ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇÏ¸é ¸Å²ãÁö´Â ±× ¹Ø¿¡ ÀÖ´Â ¹ÌºÐȼ¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ ÀÖ´Â ÀÛÀº ¹ÌºÐÈ »óÇÇ ¼¼Æ÷. |
||
| ¿µ¹® | renal cell carcinoma | ÇÑ±Û | ÄáÆÏ¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼ ¹ß»ýÇÑ ¾Ï. ÁÖ·Î ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸ÀÌ´Â ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈÇпä¹ýÀÌ¸ç ¾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù. |
||
| ¿µ¹® | squamous cell carcinoma | ÇÑ±Û | ÆíÆò¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼, ÆíÆò¼¼Æ÷°¡ ÀÖ´Â ¾î¶² °÷¿¡¼µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀÚ±Ã¾Ï µîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. ƯÈ÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢ÈÁõ¿¡¼ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Ư¼ºÀ¸·Î¼ °¢ÁúÀ» »ý¼ºÇÑ´Ù. |
||
| PBSC | peripheral blood stem cell |
|---|---|
| PHSC | pleuripotent hemopoietic stem cell |
| PMSC | pediatric medical special care; pluripotent myeloid stem cell |
| PSCT | peripheral stem cell transplantation |
| SCF | Skin Cancer Foundation; stem cell factor; subcostal frontal [view] |
| hilar cell tumour of ovary | A small benign masculinizing ovarian tumour derived from hilar cells, which resemble Leydig cells of the testis. (05 Mar 2000) |
|---|---|
| Hurthle cell tumour | A neoplasm of the thyroid gland composed of polyhedral acidophilic cells, thought by some to be oncocytes; it may be benign or malignant, the behaviour of the latter depending on the general microscopic pattern, whether follicular, papillary, or undifferentiated. See: Hurthle cell adenoma. Synonym: Hurthle cell carcinoma. (05 Mar 2000) |
| sertoli cell tumour | A rare benign tumour of the testis that histologically resembles the foetal testis. There are three varieties: diffuse stromal, mixed (stromal and epithelial), and tubular (epithelial). Sertoli cells in the epithelial elements may produce oestrogen and cause feminization. (12 Dec 1998) |
| sertoli-leydig cell tumour | An ovarian tumour usually of low-grade malignancy occurring most frequently in the third and fourth decades, with 75% seen in women under 40. It is rare, representing less than .02% of ovarian cancers. The tumour typically produces androgens with virilization being noted in 70-85% of the patients. (holland et al., cancer medicine, 3d ed, p1684) (12 Dec 1998) |
| interstitial cell tumour of testis | <tumour> A small benign tumours of the testis that often produce testosterone, causing endocrine symptoms. Synonym: interstitial cell tumour of testis. (05 Mar 2000) |
| ovarian granulosa-theca cell tumour | <radiology> Any age, most benign, oestrogens may lead to isosexual precocious puberty (pathognomonic), large tumour with areas of cystic degeneration (12 Dec 1998) |
| theca cell tumour | A sex cord-stromal tumour of the postmenopausal ovary that is yellow, large, and unilateral, composed of fascicles of lipid-rich spindle cells interspersed with collagen, reticulin fibres, and hyaline plaques. Thecomas and other oestrogen-producing tumours (e.g., granulosa cell tumours) may induce adenomatous hyperplasia of the endometrium or well-differentiated endometrial carcinoma in 3%-20% of the cases. (12 Dec 1998) |
| tumour cell | <oncology> Cell derived from a tumour in an animal. Refers to a tumour causing malignant cell and not an adventitious normal cell. Loosely, a transformed cell able to give rise to tumours. (18 Nov 1997) |
| leydig cell tumour | The most common nongerminal tumour of the testis, derived from the leydig cells. It is rarely malignant. This tumour appears among 1-3% of testicular tumours and although they may be seen in children, the median age of appearance is 60 years. They are sometimes seen in women as ovarian tumours. Clinically, symptoms are usually related to the endocrine abnormalities induced by this tumour. (12 Dec 1998) |
| acetyl reduction assay | <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase. (06 May 1997) |
| Ames assay | <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria. (18 Nov 1997) |
| antibiotic assay | <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical. (09 Oct 1997) |
| assay | <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug. (10 May 1997) |
| bandshift assay | <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences. A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound. (18 Nov 1997) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|